Physician profile
James G Chun
NPI 1134143506
$8,804.03
in general payments reported to CMS, 2019-2025
26 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,600 · 2020: $719 · 2021: $1,108 · 2022: $478 · 2023: $182 · 2024: $419 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558 · Consulting Fee: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.93 |
| Consulting Fee | $342.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $4,197.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $2,200.23 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.42 | 2019-2021 | |
| Amgen INC. | $308.48 | 2019-2022 | |
| Ge Healthcare | $275.00 | 2024 | |
| Bardy Diagnostics, INC. | $272.70 | 2020-2022 | |
| Abbott Laboratories | $178.16 | 2019-2025 | Assurity, Aveir, Jot Dx |
| Baxter Healthcare | $175.10 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $147.73 | 2019-2025 | Jetstream Sc, Ranger |
| Medtronic, INC. | $112.17 | 2021-2023 | Telescope |
| Abiomed | $111.10 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $84.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $79.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $61.70 | 2019-2021 | |
| Pfizer INC. | $53.12 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.37 | 2019 | |
| Novo Nordisk INC | $24.26 | 2024 | Ozempic |
| Esperion Therapeutics, INC. | $23.72 | 2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $21.35 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $18.22 | 2024 | Zio Xt Patch, Zio Monitor |
| Octapharma USA, INC. | $18.19 | 2025 | Balfaxar |
| Cordis US Corp. | $17.46 | 2025 | Mynx Control Venous |
| Heartflow, INC. | $16.04 | 2019 | |
| Penumbra, INC. | $14.77 | 2023 | Indigo System |
| Kowa Pharmaceuticals America, INC. | $12.48 | 2022 | |
| Cardiovascular Systems INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.